UFP Technologies Signals Growth Momentum Amid Short-Term Drags

Ufp Technologies ((UFPT)) has held its Q1 earnings call. Read on for the main highlights of the call.

UFP Technologies’ latest earnings call struck an upbeat tone despite some near‑term bumps. Management highlighted solid medical growth, rising margins, and surging output from low‑cost facilities, while acknowledging softer nonmedical demand, start‑up expenses, and a one‑off cyber disruption. The message was clear: temporary pressure now, but confidence in the long‑term trajectory remains intact.

Top-line growth anchored by resilient medical demand

Revenue rose 4.1% year over year as total sales increased about 4%, powered by a 5.9% jump in the core medical business. Strength in robotic‑assisted surgery, patient surfaces and support, and interventional and surgical markets offset weakness elsewhere, underscoring how UFP’s portfolio is increasingly tilted toward higher‑value healthcare applications.

Submarket strength in key medical niches

Within medical, several strategic niches delivered standout performance, with robotic surgery revenue up 7% and patient surfaces and support climbing 11%. Interventional and surgical products led the pack with 15% growth, showing that UFP is successfully capturing share in procedure‑driven markets that benefit from long‑term demographic and technology trends.

Margin improvement despite operational friction

Gross margin edged up to 28.8% from 28.5% a year ago, a modest but notable gain given ongoing labor inefficiencies at the AJR operation. The improvement signals underlying pricing power and mix benefits from higher‑margin medical programs even as certain facilities still work through productivity challenges.

Adjusted profitability metrics remain solid

Adjusted operating margin came in at 16.7% of sales, reflecting resilient underlying profitability. Adjusted diluted EPS was $2.48, up slightly year over year, as operational progress and favorable mix offset headwinds from start‑up costs, legal expenses, and labor-related inefficiencies.

Capacity expansion driven by strong program demand

Operationally, management highlighted that three of four new program launches have already prompted customers to request at least double the originally planned capacity. To meet this demand, UFP is adding a third building in Santiago and a sixth in La Romana, both expected in the second quarter, and is planning further expansion in the Asia‑Pacific region to support global growth.

Low-cost Dominican operations scaling rapidly

The company’s Santiago, Dominican Republic facility saw revenue increase by more than 200%, dramatically improving absorption of fixed overhead. This rapid scale‑up not only lowers unit costs but also reinforces UFP’s strategy of shifting more production to cost‑advantaged locations while maintaining quality and service levels for medical customers.

Healthy balance sheet and measured cash deployment

UFP generated roughly $3.2 million of operating cash in the quarter and used excess liquidity to reduce leverage, paying down about $4 million of debt since March 31. The company ended the period with leverage around 1.14x and kept capital expenditures modest at $1.7 million, maintaining flexibility for future growth investments.

M&A remains a key strategic growth lever

Management reported that prior acquisitions, including three completed in 2025 and four in 2024, are performing well and integrating as planned. The company continues to actively evaluate deals but stressed a disciplined approach focused on valuation and strategic fit, positioning mergers and acquisitions as a meaningful driver of growth over the coming years.

Orderly leadership transition supports continuity

An upcoming CEO transition in June to Mitch Rock was framed as well‑planned and orderly, with the outgoing chief executive staying on as executive chair. Management emphasized that this structure should ensure strategic continuity and support ongoing execution as UFP navigates its next phase of expansion.

Nonmedical sales decline as portfolio is reshaped

Nonmedical revenue fell 15% year over year as UFP continues to exit or de‑emphasize lower‑fit areas, including parts of the automotive segment. The company also cited softness in some advanced component markets, reinforcing its strategy to lean harder into medical and other higher‑margin, more defensible end markets.

Flat organic sales amid program ramps

Organic sales were essentially flat in the quarter, reflecting early ramp stages for several new programs and weaker nonmedical demand. Management framed this as a timing issue rather than a structural concern, with expectations that as these programs scale, organic growth will re‑accelerate in coming periods.

EPS tempered by start-up and one-off costs

Earnings per share growth lagged revenue as four simultaneous program launches generated start‑up expenses and AJR’s labor turnover pressured costs. Nonrecurring legal expenses tied to a cyber event and the CEO transition added further drag, masking some of the underlying earnings power of the business.

Cyber event shifts revenue and adds legal costs

A cyber incident at a key customer delayed roughly $1 million of sales from the first quarter into the second, creating a temporary revenue headwind. The episode also produced about $0.5 million in one‑time legal expenses, which flowed through the quarter’s results but are not expected to recur.

Higher SG&A reflects growth investments and one-timers

Selling, general, and administrative expenses rose by $2.2 million to $21 million, with about $750,000 tied to additional wages and benefits for back‑office support. The increase also included roughly $0.5 million in noncash equity compensation and about $0.5 million in one‑time legal costs, indicating a mix of structural and temporary drivers.

Wound care slowdown seen as temporary

The wound care business declined as two major customers slowed orders to work through excess inventory, weighing on short‑term growth. Management expects this digestion phase to last around three quarters before normalizing and sees potential for new programs in this segment next year.

Labor inefficiencies at AJR weigh on costs

The AJR facility continues to face labor productivity issues and turnover‑related inefficiencies, partly linked to E‑Verify implementation, which are pressuring cost of sales. UFP plans to gradually address these issues and leverage transfers to lower‑cost sites such as Santiago, but noted that fully resolving them will take time.

Input cost volatility tied to geopolitical risks

Rising oil prices, influenced by geopolitical conflict in the Middle East, are creating inflationary pressure on raw materials and adding uncertainty around input costs. While tariff exposure is currently net favorable, management expects oil‑driven cost increases to be passed through to customers where possible, with ongoing volatility a watch point.

Working capital dynamics limit near-term cash flow

Operating cash flow of about $3.2 million was below the company’s typical seasonal pattern as a strong March sales month drove higher working capital needs. This timing effect reduced free cash generation in the quarter but is not seen as a structural change in UFP’s ability to convert earnings into cash.

Forward-looking guidance and growth outlook

Looking ahead, management expects new‑program revenue to accelerate in the second half of 2026 as four major launches ramp, three of which already face requests to double capacity. They also anticipate recovering the $1 million of sales shifted into the second quarter, passing through raw‑material inflation, benefiting from lower effective tariffs, leveraging fresh capacity in La Romana and Santiago, and using acquisitions to drive roughly half of long‑term growth.

UFP Technologies’ earnings call painted a picture of a company investing through temporary headwinds to strengthen its medical‑focused, low‑cost manufacturing platform. While near‑term organic growth and EPS are constrained by program ramps, labor friction, and a softer nonmedical backdrop, expanding capacity, strong submarket demand, and active M&A suggest a constructive long‑term setup for investors focused on fundamentals.